Relenza Divorce Coming? Developer Sues GSK For Lack Of Support
This article was originally published in The Pink Sheet Daily
Executive Summary
Biota, the Australian firm which developed the flu treatment, says that GlaxoSmithKline has stopped promoting Relenza and has declined to expand its label, allowing market share to “freefall.”
You may also be interested in...
GSK Seeks Manufacturing Partners For Flu Treatment Relenza
The antiviral’s inhaler system may pose manufacturing hurdles for third parties, CEO Garnier concedes.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.